drugset / Trial / NCT00151086
Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
Purpose: This clinical trail will combine the chemotherapy drugs, Estramustine and Vinorelbine (Navelbine), on an intermittent therapy strategy based on PSA response in the treatment of hormone refractory prostate cancer. The investigators will determine the tolerable dose of (oral) vinorelbine in combination with (oral) estramustine, and evaluate the efficacy of this treatment for patients with hormone-refractory prostate cancer.
Timeline
- Start
- 2001-12
- Primary completion
- 2004-03
- Completion
- 2006-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vinorelbine | Small molecule | 50 mg/m2 | Oral |
| Subject | estramustine | Other / unclassified | 140 mg | Oral |